Table 2. Interval mean values for plasma lipid and lipoprotein concentrations before and mean values (patients N2 and N4) and interval mean values (patients N1 and N3) after lomitapide treatment in the HoFH patients.

Patient	Before	After	mg/dl Changes	% Changes
N1
TC	527 ± 72	329 ± 49	−198	−38
TG	128 ± 51	64 ± 16	−64	−50
HDL	30 ± 6	32 ± 5	2	7
LDL	472 ± 65	305 ± 51	−167	−35
N2
TC	388 ± 23	177 ± 15	−211	−55
TG	142 ± 35	102 ± 55	−40	−28
HDL	32 ± 2	33 ± 2	1	3
LDL	330 ± 25	114 ± 15	−216	−65
N3
TC	295 ± 24	236 ± 47	−59	−20
TG	105 ± 38	69 ± 19	−36	−34
HDL	27 ± 3	25 ± 4	−2	−7
LDL	220 ± 27	196 ± 46	−24	−11
N4
TC	322 ± 40	180 ± 25	142	−45
TG	114 ± 13	70 ± 22	−34	−39
HDL	40 ± 2	45 ± 6	5	12
LDL	259 ± 38	118 ± 30	−141	−54

Before indicates the TC, TG, HDL and LDL values before adding lomitapide to regularly treatment with lipid lowering drugs and LDL apheresis sessions. In patients N2 and N4 “After” indicates mean values for blood lipids with lomitapide treatment and no LDL apheresis sessions and in patients N1 and N3 “After” indicates interval mean values after adding lomitapide and with LDL apheresis sessions. All data were expressed as mg/dl, mean ± SD. The mean data were based on last 5 measurements before and Lomitapide administration. To convert cholesterol values (TC, HDL, and LDL) from mg/dl to mmol/l, multiply by 0.0259, and, for TGs, multiply by 0.0113. TC indicates total cholesterol, TG indicates triglycerides, LDL indicates low-density lipoprotein, HDL indicates high-density lipoprotein.